Newron raises CHF4.7 million in placement

Newron Pharmaceuticals SpA of Italy has raised CHF4.7 million (€3.91 million) in a private placement of its shares ahead of the planned registration in 2013 of its lead compound for Parkinson’s disease, safinamide.